Financials in USD. Standardized financial statements.
A compact view of how Deciphera Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $163.36M | $134.04M | $96.15M | $42.09M | $25.00M | $0 | $0 | $0 | $0 |
| Revenue Growth? | +21.9% | +39.4% | +128.5% | +68.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $3.73M | $8.77M | $2.93M | $225,000 | $830,000 | $0 | $0 | $0 | $0 |
| Gross Profit? | $159.62M | $125.27M | $93.22M | $41.86M | $24.17M | $0 | $0 | $0 | $0 |
| Gross Margin? | +97.7% | +93.5% | +97.0% | +99.5% | +96.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $370.58M | $307.99M | $393.29M | $313.05M | $225.73M | $104.10M | $50.94M | $25.84M | $17.61M |
| Operating Income? | -$210.96M | -$182.72M | -$300.08M | -$271.19M | -$200.73M | -$104.10M | -$50.94M | -$25.84M | -$17.61M |
| EBITDA? | -$208.86M | -$170.75M | -$297.06M | -$264.18M | -$183.65M | -$99.77M | -$50.04M | -$25.74M | -$17.53M |
| Income Before Tax | -$194.51M | -$178.21M | -$299.96M | -$266.49M | -$192.26M | -$99.85M | -$50.28M | -$25.94M | -$19.82M |
| Income Tax Expense | $431,000 | $722,000 | -$3.13M | $0 | -$763,000 | $0 | $0 | $110,000 | $3,000 |
| Net Income? | -$194.94M | -$178.93M | -$296.84M | -$266.49M | -$191.49M | -$99.85M | -$50.28M | -$25.94M | -$19.82M |
| EPS? | $-2.29 | $-2.37 | $-5.11 | $-4.78 | $-4.47 | $-2.82 | $-2.99 | $-1.24 | $-0.95 |
| Diluted EPS? | $-2.29 | $-2.37 | $-5.11 | $-4.78 | $-4.47 | $-2.82 | $-2.99 | $-1.24 | $-0.95 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality